false
0001175151
0001175151
2026-11-19
2026-11-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 19, 2026
CYTOSORBENTS CORPORATION
(Exact name of registrant as specified in
its charter)
| Delaware |
|
001-36792 |
|
98-0373793 |
(State or other
jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
305
College Road East, Princeton, New Jersey |
|
08540 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (973) 329-8885
| |
| (Former name or former address, if changed since last report.) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
| Common Stock, $0.001 par value |
CTSO |
The Nasdaq Stock Market LLC
(Nasdaq Capital Market) |
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
| ¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01 Entry into a Material Definitive Agreement.
On November 19, 2026,
CytoSorbents Corporation (the “Company”), a Delaware corporation, entered into two securities purchase agreements
(collectively, the “Purchase Agreements”) with certain institutional and accredited investors (collectively, the
“Purchasers”), for the sale by the Company directly to the Purchasers (the “Offering”) of (i) an aggregate
of 556,681 shares (the “Common Shares”) of the Company’s common stock, par value $0.001 per share (the
“Common Stock”), at a purchase price of $4.94 per share, and 96,527 shares of Common Stock to the Company’s
directors and certain executive officers at an offering price of $5.18 per share, which was the consolidated closing bid price of
our Common Stock on The Nasdaq Capital Market on November 18, 2026, and (ii) to certain Purchasers, in lieu of Common Stock,
pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 151,822 shares of Common Stock (the
“Pre-Funded Warrant Shares,” together with the Common Shares, the “Shares”), at a purchase price of $4.939
per Pre-Funded Warrant, equal to the purchase price per Common Share less $0.001, each exercisable for one share of Common Stock at
an exercise price of $0.001 per Pre-Funded Warrant Share. The Shares and Pre-Funded Warrants are referred to herein as the
“Securities.”
In connection with the Offering,
H.C. Wainwright & Co., LLC (“Wainwright”) is acting as exclusive placement agent for the Offering. WBB Securities, LLC
(“WBB”) is acting as financial advisor for the Offering, and will receive a financial advisory fee of $30,000 in connection
therewith.
The Offering is expected
to close on or about November 20, 2026, subject to satisfaction of customary closing conditions set forth in the Purchase
Agreements. The gross proceeds from the Offering, before deducting placement agent fees, financial advisor fees and other offering
expenses payable by the Company, will be approximately $4.0 million. The Company estimates that net proceeds from the Offering will
be approximately $3.5 million. The Company currently intends to use the net proceeds from the Offering for (i) the repayment of $3.0
million of outstanding principal under the Company’s Loan Agreement with Avenue (as defined below), together with a $52,500
prepayment fee and a $270,000 final payment, and (ii) general corporate and working capital purposes.
The Securities were offered
by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-281062), which was initially filed with the Securities
and Exchange Commission (the “Commission”) on July 26, 2024 and was declared effective by the Commission on September 30,
2024 (the “Registration Statement”), including the base prospectus dated September 30, 2024, as supplemented by a prospectus
supplement filed with the Commission on November 20, 2026, pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the
“Securities Act”). In addition, the Registered Shares (as defined below) to be issued to Avenue pursuant to the Avenue Amendment,
as described below, are being offered pursuant to the Registration Statement, the base prospectus included therein and the prospectus
supplement filed pursuant to Rule 424(b)(5) under the Securities Act.
The
Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in
full, subject to the Beneficial Ownership Limitation described below. A holder of a Pre-Funded Warrant may not exercise any such Pre-Funded
Warrant to the extent that such exercise would result in the number of shares of Common Stock beneficially owned by such holder and its
affiliates exceeding 4.99% or 9.99% (at the election of the holder) of the total number of shares of Common Stock outstanding immediately
after giving effect to the exercise, which percentage may be increased or decreased at the holder’s election not to exceed 9.99%
(the “Beneficial Ownership Limitation”).
The Purchase Agreements contain
customary representations, warranties, covenants and agreements by the Company and the Purchasers, customary conditions to closing, indemnification
obligations of the Company and other obligations of the parties. The representations, warranties and covenants contained in the Purchase
Agreements were made only for purposes of the Purchase Agreements and as of specific dates, were solely for the benefit of the parties
thereto, and may be subject to qualifications and limitations agreed upon by the contracting parties, including standards of materiality
and knowledge that may differ from those applicable to investors generally. Accordingly, such representations, warranties and covenants
should not be relied upon as characterizations of the actual state of facts or condition of the Company.
Placement Agent Common Stock Warrant
On October 5, 2026, the
Company entered into an engagement letter with Wainwright in connection with the Offering (as amended, the “Engagement
Letter”), pursuant to which Wainwright agreed to serve as the exclusive placement agent in connection with the Offering. As
compensation for such placement agent services, the Company has agreed to pay Wainwright an aggregate cash fee equal to 6.0% of the
aggregate gross proceeds received by the Company from the Offering, reduced to 3.0% with respect to gross proceeds received from
certain existing stockholders of the Company identified in the Engagement Letter, together with their respective affiliates and
affiliated funds and accounts (the “Company Investors”), and to issue to Wainwright or its designees warrants (the
“Placement Agent Warrants”) to purchase a number of shares of Common Stock (the “Placement Agent Warrant
Shares”) equal to 6.0% of the aggregate number of shares of Common Stock (or Common Stock equivalents, if applicable) issued
in the Offering, reduced to 3.0% with respect to the shares of Common Stock (or pre-funded warrants in lieu thereof) purchased by
the Company Investors. The Company also agreed to pay to Wainwright non-accountable expenses of $50,000, up to $100,000 for its fees
and expenses of legal counsel and other out-of-pocket expenses and closing costs, including clearing costs not to exceed $15,950,
subject to an aggregate cap of $165,950 on such expenses and reimbursements. The Engagement Letter also includes indemnification
obligations of the Company and other provisions customary for transactions of this nature.
The Placement Agent Warrants, exercisable
into 18,078 shares of Common Stock, will have an exercise price of $6.175 per share, subject to customary adjustment as provided
therein, will be immediately exercisable and will expire on November 19, 2031. Under the terms of the Placement Agent Warrants, the
Company may not effect the exercise of any portion of any Placement Agent Warrants, and a holder will not have the right to exercise
any portion of any Placement Agent Warrants, which, upon giving effect to such exercise, would cause a holder (together with its
affiliates) to own more than a specified beneficial ownership limitation of 4.99% of the number of shares of Common Stock
outstanding immediately after giving effect to such exercise, as such percentage ownership is determined in accordance with the
terms of the Placement Agent Warrants. However, any holder may increase or decrease such percentage to any other percentage not in
excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after such notice is delivered
to the Company.
The Placement Agent Warrants and the shares of
Common Stock issuable upon exercise of the Placement Agent Warrants are not being registered under the Securities Act, were not offered
pursuant to the Registration Statement and were offered pursuant to the exemption from registration provided by Section 4(a)(2) of the
Securities Act, and Rule 506(b) promulgated thereunder.
Third
Amendment to the Avenue Capital Loan Agreement
Concurrently with the execution
of the Purchase Agreements relating to the Offering, the Company entered into the Third Amendment to Loan Documents (the “Avenue
Amendment”), dated November 19, 2026, to its existing Loan and Security Agreement with Avenue Capital Group, as amended (the “Loan
Agreement”), pursuant to which the Company agreed to restructure certain of its outstanding indebtedness under the Loan Agreement.
Under the terms of the Avenue
Amendment, the Company agreed to (i) repay approximately $3.3 million of outstanding indebtedness under the Loan Agreement in cash, consisting
of $3.0 million in outstanding principal, a $52,500 prepayment fee and a $270,000 final payment, and (ii) satisfy an additional $2.25
million of outstanding principal through the issuance of shares of Common Stock to Avenue Venture Opportunities Fund, L.P. (“Avenue”)
in lieu of repayment in cash. Such shares will be issued at a price per share equal to the purchase price per share of Common Stock sold
in the Offering, or $4.94 per share. Of these shares, 202,429 shares, representing the satisfaction of $1.0 million of outstanding principal (the “Registered
Shares”), are being issued pursuant to the Registration Statement, the related prospectus and the applicable prospectus supplement,
and the remaining 253,036 shares of Common Stock (the “Unregistered Shares” and, together, with the Registered Shares, the
“Avenue Shares”), representing the satisfaction of $1.25 million of outstanding principal, are being offered pursuant to the
exemption from registration provided in Section 4(a)(2) under the Securities Act, and Rule 506(b) promulgated thereunder.
The cash repayment and issuance
of shares of Common Stock pursuant to the Avenue Amendment are expected to occur substantially concurrently with the closing of the Offering,
subject to satisfaction of the applicable conditions under the Avenue Amendment. Upon issuance of all shares in satisfaction of the additional
$2.25 million of outstanding principal, such principal will be deemed paid and satisfied in full. Upon completion of the $3.0 million
cash principal repayment and the issuance of shares in satisfaction of the additional $2.25 million of outstanding principal, the Company
expects the outstanding principal amount under the Loan Agreement to be reduced by approximately $5.25 million in the aggregate, to a remaining total of $12.25 million of outstanding principal.
The Avenue Amendment also
(i) extends the interest-only period through March 31, 2028, subject to a possible three-month extension upon achievement of FDA Marketing
Approval and the absence of a continuing event of default, and establishes a maturity date of July 1, 2028; (ii) revises the lenders’
rights to convert up to $3,000,000 of outstanding principal at 140% of the defined Trading Price, or $6.916 per share, and upon the earlier of FDA Marketing
Approval or January 1, 2028, up to an additional $3,125,000 of outstanding principal at 175% of that Trading Price, or $8.645 per share, in each case subject
to the conditions and limitations in the Avenue Amendment; (iii) imposes a 4.99% beneficial ownership limitation, subject to adjustment
on notice, and a 19.99% exchange cap, absent requisite stockholder approval, on issuances upon exercise of the applicable conversion options
and warrants; and (iv) increases the applicable cash-burn threshold to $3,200,000 for testing periods through December 31, 2026, with
a $2,000,000 threshold otherwise applicable under the amended covenant.
The Avenue Amendment further
provides for a $250,000 back-end fee payable to Avenue on July 1, 2028 (or earlier upon repayment or acceleration of the obligations),
subject to waiver if Avenue realizes the specified 300% net-profit threshold on the Avenue Shares. It also provides Avenue registration
rights with respect to the shares issued in the transaction exempt from registration under the Securities Act, pursuant to which the Company
has agreed to file a resale registration statement within 60 days after the Avenue Amendment effective date and to use commercially reasonable
efforts to cause it to become effective within 90 days after that date, subject to the terms of the Avenue Amendment. Certain shares issuable
to the Lenders upon exercise of conversion options or warrants are subject to a transfer restriction tied to the prohibition period under
the Securities Purchase Agreement, as described in the Avenue Amendment.
The foregoing descriptions
of the Pre-Funded Warrants, the Placement Agent Warrants, each of the Purchase Agreements and the Avenue Amendment are not complete and
are qualified in their entirety by reference to the full text of the Form of Pre-Funded Warrant, the Form of Placement Agent Warrant,
each of the Forms of Purchase Agreement and the Avenue Amendment, which are filed herewith as Exhibits 4.1, 4.2, 10.1, 10.2, and 10.3,
respectively, to this Current Report on Form 8-K and are incorporated by reference herein.
A copy of the opinion of Morgan,
Lewis & Bockius LLP relating to the legality of the issuance and sale of the Shares, the Pre-Funded Warrants and the Registered Shares
in the Registered Direct Offering is filed as Exhibit 5.1 to this Current Report on Form 8-K.
This Current Report on Form
8-K does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.
Forward-Looking Statements
This Current Report on Form
8-K contains forward-looking statements that involve risks and uncertainties, such as statements related to the expected use of the proceeds
from the Offering. There are a number of important factors that could cause actual results to differ materially from those indicated or
implied by forward-looking statements. Accordingly, you are cautioned that these forward-looking statements are only predictions and are
subject to risks, uncertainties and assumptions, including those referenced from time to time in the Company’s periodic reports
and other filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements, which are based on the Company’s
current expectations and assumptions and speak only as of the date of this Current Report on Form 8-K. The Company does not intend to
revise or update any forward-looking statement in this Current Report on Form 8-K as a result of new information, future events or otherwise,
except as required by law.
Item 3.02 Unregistered Sales of Equity Securities.
The information under Item
1.01 of this Current Report on Form 8-K related to the Placement Agent Warrants, the Placement Agent Warrant Shares and the Unregistered
Shares is incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
On November 20, 2026, the
Company issued a press release relating to the items discussed in Item 1.01 of this Current Report on Form 8-K, a copy of which is furnished
as Exhibit 99.1 hereto.
The information in this Item
7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference
into any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. |
Description |
| 4.1 |
Form of Pre-Funded Warrant |
| 4.2 |
Form of Placement Agent Common Stock Warrant |
| 5.1 |
Opinion of Morgan, Lewis & Bockius LLP |
| 10.1 |
Form of Securities Purchase Agreement, dated November 19, 2026, by and between CytoSorbents Corporation and the purchasers named therein |
| 10.2 |
Form of Securities Purchase Agreement, dated November 19, 2026, by and between CytoSorbents Corporation and the purchasers named therein |
| 10.3 |
Third Amendment to Loan Documents, dated November 19, 2026, among CytoSorbents Corporation, Avenue Capital Management II, L.P., Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P. |
| 23.1 |
Consent of Morgan, Lewis & Bockius LLP (included in Exhibit 5.1) |
| 99.1 |
Press Release dated November 20, 2026 |
| 104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| November 20, 2026 |
CytoSorbents Corporation |
| |
|
| |
By: |
/s/ Dr. Phillip P. Chan |
| |
|
Name: |
Dr. Phillip P. Chan |
Exhibit 99.1
CytoSorbents Announces $6.25 Million Common
Stock Financing Priced At-the-Market under Nasdaq Rules and Concurrent Restructuring of Avenue Capital Credit Facility
$4.0 million registered direct offering of common
stock, led by existing shareholders and management
$2.25 million of Avenue debt satisfied through
the issuance of common stock at the same offering price
Total debt reduced by $5.25 million, to $12.25
million, saving approximately $0.7 million in interest over 12 months
Maturity extended one year to July 1, 2028;
interest-only period extended 15 months through March 31, 2028
PRINCETON, N.J., November 20, 2026 -- CytoSorbents Corporation (NASDAQ:
CTSO, the “Company”), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery
using blood purification, today announced a $6.25 million common stock financing.
Registered Direct Offering
The Company has entered into securities purchase agreements with certain
institutional and accredited investors and certain insiders of the Company for the issuance and sale in a registered direct offering (the
“Offering”) priced at-the-market under Nasdaq rules of (i) an aggregate of 556,681 shares (the “Common Shares”)
of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $4.94 per share,
and 96,527 shares of Common Stock to the Company’s directors and certain executive officers at an offering price of $5.18 per share,
which was the consolidated closing bid price of our Common Stock on The Nasdaq Capital Market on November 18, 2026, and (ii) pre-funded
warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 151,822 shares of Common Stock (the “Pre-Funded
Warrant Shares,” together with the Common Shares, the “Shares”), at a purchase price of $4.939 per Pre-Funded Warrant,
equal to the purchase price per Common Share less $0.001. Each Pre-Funded Warrant is immediately exercisable for one share of Common Stock
at an exercise price of $0.001 per Pre-Funded Warrant Share until such Pre-Funded Warrants are exercised in full.
The Offering is expected to consist of approximately $4.0 million of
gross cash proceeds, with approximately 75% of the Offering subscribed for by existing shareholders and members of the Company’s
management and Board of Directors.
H.C. Wainwright & Co. is acting as exclusive placement agent
for the Offering. WBB Securities LLC is acting as financial advisor in connection with the Offering.
The Offering is expected to close on or about November 20, 2026,
subject to satisfaction of customary closing conditions. Gross proceeds from the Offering are expected to be approximately $4.0 million,
before deducting placement agent fees, financial advisor fees and offering expenses payable by the Company. The Company intends to use
the net proceeds for (i) the repayment of $3.0 million of outstanding principal under its existing loan agreement with Avenue Capital
Group (“Avenue”), together with a $52,500 prepayment fee and a $270,000 final payment, and (ii) general corporate and working capital purposes.
Avenue Credit Facility Amendment
Concurrently with the Offering, the Company entered into the Third
Amendment to Loan Documents (the “Avenue Amendment”), dated November 19, 2026, to its existing Loan and Security Agreement
dated June 28, 2024, as amended, with Avenue. Key terms include:
| · | Debt reduction of $5.25 million: Repayment of $3.0 million of principal in cash from
the Offering proceeds, plus a $52,500 prepayment fee and a $270,000 final payment, and satisfaction of $2.25 million of principal
through the issuance of 455,465 shares of Common Stock to Avenue Venture Opportunities Fund, L.P. at the Offering price of $4.94 per share. Following
these transactions, $12.25 million of principal will remain outstanding, down from $17.5 million. The Company expects to save
approximately $0.7 million in interest expense over 12 months. |
| · | Maturity extended one year: The maturity date is extended
from July 1, 2027 to July 1, 2028. |
| · | Interest-only period extended 15 months: Interest-only
payments are extended through March 31, 2028, with a further three-month extension available if the Company has received FDA marketing
approval for DrugSorb-ATR by that date, subject to other conditions. |
| |
· |
New conversion rights: Avenue’s existing $2.0 million conversion right is replaced with the right to convert (i) up to $3.0 million of principal into Common Stock at $6.916 per share, equal to 140% of the $4.94 Offering price, exercisable at any time, and (ii) up to an additional $3.125 million of principal at $8.645 per share, equal to 175% of the Offering price, exercisable beginning on the earlier of FDA marketing approval of DrugSorb-ATR and January 1, 2028. Any conversion would further reduce the Company’s outstanding debt. |
| · | Other terms: The Avenue Amendment also modifies certain
beneficial ownership limitations and financial covenants, provides certain registration rights and provides for a back-end fee of $250,000,
payable on July 1, 2028 (or earlier repayment) and waived if Avenue achieves a net profit of at least 300% on the initial $2.25 million
repayment shares. |
Of the shares issued to Avenue in satisfaction of $2.25 million of
principal, shares satisfying $1.0 million of principal (the “Registered Shares”) will be issued pursuant to the Company’s
effective shelf registration statement on Form S-3 (File No. 333-281062), and shares satisfying the remaining $1.25 million of principal
will be issued in a transaction exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”).
The shares issued to Avenue are in addition to the securities issued in the Offering and will not generate additional cash proceeds to
the Company. The cash repayment and issuance of shares to Avenue in satisfaction of the Company’s indebtedness are expected to occur
substantially concurrently with the closing of the Offering, subject to applicable closing conditions.
Registration and Offering Information
The Common Shares, Pre-Funded Warrants, Pre-Funded Warrant Shares and
Registered Shares are being offered and sold pursuant to a “shelf” registration statement on Form S-3 (File No. 333-281062),
which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on September 30, 2024. The Offering
is being made only by means of a prospectus supplement and accompanying prospectus forming part of the effective registration statement.
A final prospectus supplement and accompanying prospectus relating to the Offering and the Registered Shares will be filed with the SEC.
Electronic copies may be obtained, when available, on the SEC’s website at www.sec.gov or by contacting H.C. Wainwright & Co.,
LLC, 430 Park Avenue, 3rd Floor, New York, New York 10022, at placements@hcwco.com or (212) 856-5711.
The shares issued to Avenue in satisfaction of the remaining $1.25
million of principal are being issued in a transaction not involving a public offering and have not been registered under the Securities
Act or applicable state securities laws. Such shares may not be offered or sold in the United States absent registration or an applicable
exemption from registration. The Company has agreed to file a registration statement with the SEC covering the resale of these shares.
This press release shall not constitute an offer to sell or the solicitation
of an offer to buy any of the securities described herein, and there shall not be any offer, solicitation or sale of such securities in
any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening
conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary blood purification
technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily
fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the
hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines),
where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into
the body. CytoSorbents’ technologies are used in a number of broad applications. Specifically, two important applications are 1)
the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory
agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of
these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and
pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin
in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there
are few, if any, effective treatments.
CytoSorbents’ lead product, CytoSorb®, is approved
in the European Union and distributed in over 70 countries worldwide, with more than 300,000 devices used cumulatively to date. CytoSorb
was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted
for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban
removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use
in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb is not yet approved or cleared in
the United States.
In the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR
antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity
of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough Device Designations:
one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary
bypass circuit during urgent cardiothoracic surgery. The Company is actively pursuing regulatory approval of DrugSorb-ATR with the U.S.
FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA. DrugSorb-ATR is not yet granted or approved
in either the U.S. or Canada.
The Company has numerous marketed products and products
under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered
trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™,
VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, PuriFi®, HotSwap®, and others. For more information, please visit
the Company’s website at https://ir.cytosorbents.com/ or follow us on Facebook and X.
Forward Looking Statements
This press release includes forward-looking statements intended to
qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations
and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms
such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,”
“believe,” “estimate,” “predict,” “potential,” “continue” and similar words,
although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press
release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially
from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited
to, statements regarding the completion and timing of the Offering, the satisfaction of customary closing conditions related to the Offering,
and the intended use of net proceeds from the Offering, the expected repayment and conversion of indebtedness under the Avenue Amendment,
the expected reduction in interest expense, any future exercise of Avenue’s conversion rights, and the timing and outcome of FDA
review of DrugSorb-ATR, and the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 30, 2026, as updated by
the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by
us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. There can be no
assurance that the Company will be successful in maintaining its listing of its common stock on the Nasdaq Capital Market. We caution
you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal
securities laws.
U.S. Company Contact:
Peter J. Mariani, Chief Financial Officer
305 College Road East
Princeton, NJ 08540
ir@cytosorbents.com